hVIVO plc (AIM:HVO)

Market Cap	117.36M
Revenue (ttm)	66.22M
Net Income (ttm)	10.65M
Shares Out	680.37M
EPS (ttm)	0.02
PE Ratio	11.13
Forward PE	13.93
Dividend	0.00 (1.14%)
Ex-Dividend Date	May 15, 2025

Volume	227,027
Average Volume	1,479,535
Open	17.45
Previous Close	17.25
Day's Range	17.22 - 17.45
52-Week Range	12.60 - 31.00
Beta	1.34
RSI	53.26
Earnings Date	Jun 10, 2025

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom. The company is involved in testing of vaccines and antivirals using human challenge clinical trials; and offers laboratory services, including assay development, cell based assays, compound efficacy and VRM, field trial bio-logistics, molecular, and biomarker analysis services. It provides services to big pharma and biotech organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19,...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Yamin Khan
• Employees: 301
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: HVO

Financial Performance

In 2024, hVIVO's revenue was 66.22 million, an increase of 12.87% compared to the previous year's 58.67 million. Earnings were 10.65 million, a decrease of -33.90%.